Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma

Source: OncLive, November 2020

Geoffrey T. Gibney, MD, co-leader, Melanoma Disease Group and a member of the Developmental Therapeutics (Phase I) program at the Lombardi Comprehensive Cancer Center and MedStar Cancer Network, MedStar Georgetown University Hospital, discusses selecting between BRAF inhibitor regimens in melanoma.

Patients with BRAF-mutant unresectable stage III or active stage IV melanoma can receive BRAF-targeted therapy or immunotherapy with anti–PD-L1 agents, Gibney explains.

If targeted therapy is selected, choosing between available BRAF inhibitor combinations can be challenging, says Gibney.

READ THE ORIGINAL FULL ARTICLE